XLO - Xilio Therapeutics, Inc. Stock Price and Quote

XLO [NASD]

Index	-	P/E	-	EPS (ttm)	-3.14	Insider Own	7.40%	Shs Outstand	27.40M	Perf Week	41.79%
Market Cap	105.28M	Forward P/E	-	EPS next Y	-2.61	Insider Trans	0.00%	Shs Float	25.44M	Perf Month	66.81%
Income	-85.50M	PEG	-	EPS next Q	-0.82	Inst Own	67.90%	Short Float / Ratio	0.08% / 0.40	Perf Quarter	79.64%
Sales	-	P/S	-	EPS this Y	-37.30%	Inst Trans	-6.06%	Short Interest	0.02M	Perf Half Y	36.90%
Book/sh	4.61	P/B	0.86	EPS next Y	16.30%	ROA	-45.60%	Target Price	9.75	Perf Year	-72.26%
Cash/sh	5.25	P/C	0.76	EPS next 5Y	-	ROE	-55.00%	52W Range	1.95 - 14.86	Perf YTD	47.58%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-73.28%	Beta	-
Dividend %	-	Quick Ratio	8.40	Sales past 5Y	-	Gross Margin	-	52W Low	103.59%	ATR	0.39
Employees	78	Current Ratio	8.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	72.75	Volatility	17.44% 11.99%
Optionable	No	Debt/Eq	0.08	EPS Q/Q	-18.50%	Profit Margin	-	Rel Volume	2.50	Prev Close	4.28
Shortable	Yes	LT Debt/Eq	0.04	Earnings	-	Payout	-	Avg Volume	48.13K	Price	3.97
Recom	1.80	SMA20	34.73%	SMA50	51.59%	SMA200	39.76%	Volume	120,088	Change	-7.24%

Dec-21-22

Initiated

Chardan Capital Markets

Buy

Jan-10-22

Initiated

H.C. Wainwright

Buy

$36

Nov-16-21

Initiated

Raymond James

Outperform

$31

Nov-16-21

Initiated

Morgan Stanley

Overweight

$32

Nov-16-21

Initiated

Guggenheim

Buy

$40

Nov-16-21

Initiated

Cowen

Outperform

Jan-26-23 05:30AM	Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most Simply Wall St.
Jan-25-23 09:45AM	These 2 Strong Buy Penny Stocks Are on Track for Massive Gains, Say Analysts TipRanks +36.92%
Nov-23-22 07:30AM	Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12 GlobeNewswire +7.94%
Nov-09-22 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results GlobeNewswire
Nov-04-22 07:30AM	Xilio Therapeutics to Present at Cowen 6th Annual IO Next Summit GlobeNewswire
04:05PM	Loading…
Sep-22-22 04:05PM	Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference GlobeNewswire
Sep-15-22 04:05PM	Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors GlobeNewswire +15.38%
Sep-06-22 04:05PM	Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference GlobeNewswire +8.21%
Aug-11-22 09:41AM	Is Xilio Therapeutics (NASDAQ:XLO) In A Good Position To Invest In Growth? Simply Wall St.
Aug-09-22 07:30AM	Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results GlobeNewswire -26.22%
Jun-16-22 07:30AM	Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President GlobeNewswire
May-18-22 07:30AM	Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire -9.56%
May-17-22 07:30AM	Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer GlobeNewswire -5.18%
May-12-22 07:30AM	Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results GlobeNewswire
Apr-07-22 06:30AM	Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference GlobeNewswire
06:30AM	Loading…
Mar-01-22 06:30AM	Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire -7.56%
Feb-28-22 06:30AM	Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference GlobeNewswire -10.42%
Feb-07-22 05:38PM	RiverVest Venture Management LLC Buys Xilio Therapeutics Inc GuruFocus.com
Feb-03-22 06:30AM	Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day GlobeNewswire
Jan-25-22 10:27AM	Are Institutions Heavily Invested In Xilio Therapeutics, Inc.'s (NASDAQ:XLO) Shares? Simply Wall St.
Jan-20-22 07:30AM	Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors GlobeNewswire +9.79%
Jan-06-22 07:30AM	Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors GlobeNewswire
Dec-02-21 07:30AM	Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results GlobeNewswire -12.46%
Nov-12-21 07:00AM	Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting GlobeNewswire -6.69%
Oct-27-21 07:45AM	4 Stocks Insiders Are Buying Benzinga
Oct-26-21 04:05PM	Xilio Therapeutics Announces Closing of Initial Public Offering GlobeNewswire

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience